SEC Form 4 · accession 0000899243-18-013933

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

May 23, 2018

Accepted (ET)

May 24, 2018 · 5:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001631650

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F1	May 23, 2018	A	3,750	$0.00	A	26,619	D
Common Stock, $0.0001 par value^F2	holding	—	—		—	6,013,134	I	By: LVP2

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F3	$32.79	May 23, 2018	A	7,500	A	—	May 23, 2028	Common Stock	7,500	7,500	D

F1These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
F2Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. Patrick G. Enright is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.